Cell Therapy Technologies Market Size, Share, And Trends - Global Forecast 2026-2032 Automation, AI, And Allogeneic Platforms Drive 14.37% CAGR To USD 14.02 Billion


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI through closed automation, AI-enabled quality control, digital traceability, scalable processes and resilient supply chains that reduce risk, delays and operator dependency.

Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Cell Therapy Technologies Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The Cell Therapy Technologies Market research report analyzes the platforms, manufacturing systems, quality controls, and regional ecosystems supporting autologous and allogeneic therapies. Valued at a projected USD 6.25 billion in 2026, the market is forecast to grow at a CAGR of 14.37% and reach USD 14.02 billion by 2032. The analysis provides decision-makers with insights for strategic planning, technology investment, partnership development, and market entry.

Market Scope and Technology Landscape

Cell therapy technologies enable CAR T-cell therapies, tumor-infiltrating lymphocytes, natural killer cell therapies, mesenchymal stromal cell applications, hematopoietic stem cell products, and induced pluripotent stem cell-derived programs. The technology stack includes:

  • Cell isolation, activation, and expansion
  • Gene transfer and gene editing
  • Closed-system bioprocessing and single-use platforms
  • Cryopreservation and temperature-controlled logistics
  • Release testing, potency assays, and rapid microbiology
  • Chain-of-identity controls and digital batch records

Following the first U.S. FDA approvals of CAR T-cell therapies in 2017, the sector has advanced from scientific promise toward regulated commercialization. Market competition increasingly centers on the ability to scale manufacturing reliably, safely, and cost-effectively.

Transformative Market Shifts

Manufacturing is moving from manual, open, and site-specific workflows toward closed, automated, and digitally traceable operations. Modular cleanrooms, automated cell processing, single-use bioreactors, integrated analytics, and rapid testing are becoming important differentiators as developers seek to reduce contamination risk, improve consistency, and shorten vein-to-vein time.

Allogeneic therapies, iPSC-derived platforms, CRISPR engineering, non-viral delivery, and next-generation immune cell programs are expanding opportunities beyond hematologic malignancies into solid tumors, autoimmune diseases, inflammatory disorders, and regenerative medicine. Analysis of these shifts supports opportunity identification while helping organizations assess technology and commercialization risks.

Artificial Intelligence Applications

Artificial intelligence is generating value across discovery, manufacturing, quality control, and supply chain operations. Key applications include:

  • Target selection, biomarker discovery, and patient stratification
  • Construct optimization and antigen escape analysis
  • Culture performance and deviation prediction
  • Image-based assessment of cell morphology, viability, and phenotype
  • Release analytics, scheduling, and supply chain orchestration

Successful adoption requires validated datasets, GxP alignment, cybersecurity safeguards, audit trails, and human oversight. Treating AI as a governed quality and productivity layer can create a scalable competitive advantage without compromising patient safety.

Regional and Economic Bloc Insights

  • North America: Leads through biotechnology clusters, academic medical centers, venture funding, CDMO capacity, and established regulatory pathways.
  • Europe: Benefits from the advanced therapy medicinal product framework and manufacturing hubs in Germany, France, Italy, Spain, and the United Kingdom.
  • Asia-Pacific: Expands through Japan's regenerative medicine framework, China's clinical and manufacturing scale, South Korea's biopharmaceutical investment, and strong ecosystems in Australia and Singapore.
  • Latin America: Brazil and Mexico are gaining visibility, although reimbursement and cold-chain limitations remain.
  • Middle East and Africa: Gulf states are investing in specialist care and biomanufacturing, while selected African markets build capacity through research collaborations and workforce development.

ASEAN, the GCC, European Union, BRICS, and G7 markets present distinct regulatory, infrastructure, pricing, and innovation dynamics. These comparisons inform market entry strategies and enable stakeholders to prioritize geographies based on readiness, patient access, and partnership potential.

Strategic Priorities for Industry Leaders

  • Adopt closed, automated platforms that improve reproducibility and technology transfer.
  • Develop scalable processes early, particularly for autologous therapies.
  • Strengthen potency assays, digital batch records, rapid microbiology, and connected data architectures.
  • Build partnerships with hospitals, regulators, logistics providers, and CDMOs.
  • Diversify suppliers of reagents, viral vectors, media, consumables, and cryogenic logistics.

Key Takeaways from This Report

  • The market is projected to reach USD 14.02 billion by 2032 at a 14.37% CAGR.
  • Automation, closed processing, digital traceability, and quality analytics are central to commercial scale.
  • AI offers near-term value in quality control, release testing, scheduling, and manufacturing optimization.
  • Regional growth opportunities vary significantly by regulation, infrastructure, reimbursement, and manufacturing maturity.
  • Resilient supply chains and cross-sector partnerships are essential for reducing execution risk.

Key Attributes:

Report Attribute Details
No. of Pages 194
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $6.25 Billion
Forecasted Market Value (USD) by 2032 $14.02 Billion
Compound Annual Growth Rate 14.3%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Technologies Market, by Offering
7.1. Introduction
7.2. Consumables
7.3. Equipment
7.3.1. Bioreactors
7.3.2. Cell Analyzers
7.4. Software & Services
7.4.1. Data Management
7.4.2. Quality Control
8. Cell Therapy Technologies Market, by Therapy Type
8.1. Introduction
8.2. Allogeneic Cell Therapy
8.2.1. Dendritic Cells
8.2.2. Induced Pluripotent Stem Cells
8.2.3. Natural Killer Cells
8.3. Autologous Cell Therapy
8.3.1. Hematopoietic Stem Cells
8.3.2. Mesenchymal Stem Cells
8.3.3. T-Cells
8.4. Gene-Modified Cell Therapy
8.4.1. CAR-T Cell Therapy
8.4.2. TCR (T-Cell Receptor) Therapy
9. Cell Therapy Technologies Market, by Manufacturing Process
9.1. Introduction
9.2. Cell Culture
9.2.1. 2D Culture Systems
9.2.2. 3D Culture Systems
9.3. Cell Expansion
9.3.1. Adherent Culture
9.3.2. Suspension Culture
9.4. Cell Separation
9.4.1. Fluorescence-Activated Cell Sorting
9.4.2. Magnetic-Activated Cell Sorting
10. Cell Therapy Technologies Market, by Delivery Method
10.1. Introduction
10.2. Ex vivo
10.3. In vivo
11. Cell Therapy Technologies Market, by Application
11.1. Introduction
11.2. Cardiovascular Disease
11.2.1. Ischemic Heart Disease
11.2.2. Peripheral Artery Disease
11.3. Musculoskeletal Disorders
11.3.1. Osteoarthritis
11.3.2. Rheumatoid Arthritis
11.4. Neurodegenerative Diseases
11.4.1. Alzheimer's Disease
11.4.2. Parkinson's Disease
11.5. Oncology
11.5.1. Hematological Cancer
11.5.2. Solid Tumors
11.5.2.1. Breast Cancer
11.5.2.2. Lung Cancer
11.5.2.3. Prostate Cancer
12. Cell Therapy Technologies Market, by End User
12.1. Introduction
12.2. Biopharmaceutical Companies
12.3. Hospitals
12.3.1. Private Hospitals
12.3.2. Public Hospitals
12.4. Research Institutes
12.4.1. Government Research Centers
12.4.2. University Academics
13. Cell Therapy Technologies Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Latin America
13.6. Africa
13.7. Middle East
14. Cell Therapy Technologies Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. BRICS
14.5. European Union
14.6. ASEAN
14.7. GCC
15. Cell Therapy Technologies Market, by Country
15.1. Introduction
15.2. China
15.3. United States
15.4. Japan
15.5. India
15.6. Germany
15.7. United Kingdom
15.8. Australia
15.9. France
15.10. South Korea
15.11. Italy
15.12. Canada
15.13. Russia
15.14. Brazil
15.15. Mexico
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Adaptimmune Limited
17.2. Allogene Therapeutics Inc.
17.3. Atara Biotherapeutics, Inc.
17.4. Bellicum Pharmaceuticals, Inc.
17.5. Bluebird Bio Inc.
17.6. Cellectis SA
17.7. Century Therapeutics, Inc.
17.8. Charles River Laboratories International, Inc.
17.9. ElevateBio LLC
17.10. Gamida Cell Ltd.
17.11. GE HealthCare Technologies Inc.
17.12. Gilead Sciences, Inc.
17.13. Iovance Biotherapeutics, Inc.
17.14. Johnson & Johnson Services, Inc.
17.15. Legend Biotech USA Inc.
17.16. Novartis AG
17.17. Sartorius AG
17.18. STEMCELL Technologies Inc.
17.19. Takara Bio Inc.
17.20. Takeda Pharmaceutical Company Limited
17.21. Thermo Fisher Scientific Inc.
17.22. Vericel Corporation
18. Key Experts

List of Figures [23]
List of Tables [346]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20112026004107003653ID1111996351


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search